[KIMES 2020] Regenbogen to Showcase Etrebelle, a Hybrid Filler of PLA(Poly D,L-lactic) & HA(Sodium Hyaluronate)
[ Lee Eun Sil 2020-02-24 ]  

Regenbogen Co., Ltd.(President Jun Sung Park, www.iregenbogen.com) an Aesthetic Medical Device company will show their new Hybrid Filler of PLA(Poly D,L-lactic) & HA(Sodium Hyaluronate) which name is 'Etrebelle' at KIMES 2019 in Seoul, Korea on March 14-17, 2019.

'Etrebelle' is a Hybrid Filler of PLA(Poly D, L-lactide) microparticles and HA(Sodium Hyaluronate) which are approved by US FDA as biocompatible, biodegradable polymer materials, for providing immediate physical improvement of facial wrinkle and long lasting elasticity by stimulating collagenesis.

This product has been approved by KFDA(license no. 17-972) as graft/prosthesis and tested in clinical trials by Leaders clinic(Dr. Youn), Cellpark clinic(Dr. Chung), Picaso clinic(Dr. Kim) and so on to prove its differentiated efficacy from existing HA filler.

To control the treatment level and indication, 'Etrebelle' is consisted of 'Etrebelle 200mg' and 'Etrebelle 50mg' models. From this, Regenbogen Co., Ltd. is going to hold regular live seminars about complex application of its newly introduced filler with thread lifting as a major part. Regenbogen Co., Ltd. is an aesthetic medical device company providing optimum quality product with corresponding educational seminar not only internally in Korea, but throughout China, Japan, Southeast Asia, Europe and Middle East from 2012.

Global News Network 'AVING'
by Lee Eun Sil (www.aving.net)

Copyright ⓒ 2020 AVING. All Rights Reserved.   메일보내기 인쇄하기
  AVING Around the World  
    latest Mobile/Computing
Major innovation companies of KHIDI Health Industry Startup I... 2020-05-07
A total of six companies participated in the MIK Hot Spot_KHIDI Health Industry Startup Innovation Center. △ PDxen △ G
[MIK HOT SPOT_KHIDI] Jeios's smart immunity analysis predicti... 2020-05-07
Although the mortality rate of COVID-19 is low compared to SARS and MERS, the spread rate is known to be as fast as the
[MIK HOT SPOT_KHIDI] Immunomax presents self-memory T cell-ba... 2020-05-07
Immunomax, which participated in MIK Hot Spot (Made in Korea Online Exhibition) KHIDI introduced its self-memory T cell-
[MIK HOT SPOT_KHIDI] Genome & Company on its establishment, s... 2020-05-07
Genome & Company was listed in KONEX in just three years and attracted Series C investment in just five years of bus
[MIK HOT SPOT_KHIDI] Damage in mitochondria causes disease! P... 2020-05-07
Paean Biotechnology is developing anti-inflammatory and anti-cancer drugs based on mitochondria separated from human umb

Copyright ⓒ 2020 AVING. All Rights Reserved.  Contact Webmaster for more Information